Randomized Study of Human Albumin Versus Standard Fluid Therapy for Improving Outcomes in Adults with Aneurysmal Subarachnoid Hemorrhage

What this Trial Is About

Aneurysmal subarachnoid hemorrhage aSAH is a severe neurological emergency with high rates of disability and death. Despite advances in surgical techniques and imaging, outcomes remain poor, largely due to cerebral vasospasm causing delayed brain injury. This trial investigates whether using human albumin for fluid management can improve recovery compared to standard crystalloid fluids in patients with aSAH. Participants will be randomly assigned to receive either intermittent doses of 20% human albumin plus standard crystalloid fluids or standard crystalloid fluids alone to maintain normal fluid balance. Human albumin will be given as boluses totaling 1.25 gkg per day over a 7-day treatment period covering the peak risk of vasospasm days 4 to 10 after hemorrhage. Before treatment and after day 10, all patients receive standard fluid therapy. During the study, participants will be monitored through clinical assessments including the modified Rankin Scale at 14 days and 3 months to measure recovery. Secondary outcomes include observing symptomatic vasospasm, brain blood flow velocities via transcranial Doppler, and cardiac output parameters. The trial runs from August 2024 to July 2027 at a single center with follow-up lasting three months post-treatment.

Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages